Loading
IDO1 is an enzyme tumours use to burn up tryptophan, starving T cells and producing by-products that switch them off. Epacadostat blocked it but its programme ended in failure; the IO102-IO103 vaccine instead teaches T cells to attack the IDO1-expressing cells themselves. This dossier gathers the 2 products (0 approved), 6 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
The two corpus approaches differ in kind: epacadostat blocked the enzyme's chemistry, while IO102-IO103 raises T cells against cells that express IDO1 or PD-L1 in the tumour microenvironment, turning the suppressive cells themselves into targets.
| Modality | Phase 3 | Withdrawn or failed |
|---|---|---|
| Small molecule 1 | - | |
| Vaccine or virus 1 | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Completed | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302) | - | ||
| 3 | Completed | A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | - | ||
| 3 | Active | An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18) | - | ||
| 3 | - | A Phase 3, Randomized, Global Trial of Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in First-line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | - | ||
| 2 | Recruiting | Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors | - | ||
| 1/2 | Recruiting | Phase I/II Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"IDO1" OR ABSTRACT:"IDO1" OR TITLE:"IDO" OR ABSTRACT:"IDO" OR TITLE:"INDO" OR ABSTRACT:"INDO" OR TITLE:"indoleamine 2,3-dioxygenase 1" OR ABSTRACT:"indoleamine 2,3-dioxygenase 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IDO1, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/ido1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ido1.json. Licence CC BY-NC 4.0.